Exclusion Criteria:~1. History of any major disease that may interfere with safe engagement in the intervention
(especially severe liver or kidney disease, or uncontrolled diabetes).~2. Central nervous system infarct,
infection, or focal lesions of clinical significance on MRI scans.~3. Fulfills any contraindication for the use
of sirolimus as per the summary of product characteristics, including but not restricted to:~ * Current or
planned medication with a strong inhibitor of CYP3A4 or P-gp~ * Current or planned medication with a strong
inducer of CYP3A4 or P-gp~ * Other current medications with known serious interaction risks with sirolimus~ *
Known allergy or hypersensitivity to sirolimus~4. Significant obesity~5. Untreated and clinically significant
hyperlipidemia~6. Treatment with immunosuppressive medications within the last 90 days (topical and nasal
corticosteroids and inhaled corticosteroids for asthma are permitted), or chemotherapeutic agents for
malignancy within the last 3 years~7. Major surgery within 3 months prior to the planned start of sirolimus
treatment, OR has major surgery planned during the period of the trial.~8. Use of experimental medications for
Alzheimer's or any other investigational medication or device within 60 days. Participants who have been
involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in
that trial
